FOLH1 and metastatic neoplasm: In this scenario, patients with extensive metastatic disease who are candidates for PSMA therapy at tertiary care facilities can undergo baseline and follow-up imaging with PSMA at peripheral centers that lack PET infrastructure but are equipped with conventional nuclear medicine facilities [67].